Multicenter Phase II Study of Pegylated Liposomal Doxorubicin in Combination with Vinorelbine as First-Line Treatment in Elderly Patients with Metastatic Breast Cancer

Paracelsus Medical University Salzburg, 3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Disease and Laboratory of Immunological and Molecular Cancer Research, Müllner Hauptstrasse 48, Salzburg, Austria.
Onkologie (Impact Factor: 0.84). 03/2009; 32(1-2):18-24. DOI: 10.1159/000180915
Source: PubMed

ABSTRACT This multicenter phase II trial was conducted to analyze the clinical activity and toxicity of the combination of pegylated liposomal doxorubicin and vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.
From August 2002 to August 2004, 42 patients with metastatic breast cancer were recruited for treatment with pegylated liposomal doxorubicin 40 mg/m(2) intravenously (i.v.) on day 1 and vinorelbine 30 mg/m(2) i.v. on days 1 and 15 every 4 weeks.
The median age of the patients in this trial was 68 years (range 60-82). 40% of patients had 2 or more sites of metastasis, 33 (78%) had predominantly visceral metastasis, and 7 (16%) mostly bone metastasis. Just 2 (5%) patients had only lymphogenous or soft tissue metastasis. All patients had an ECOG performance status of 0-1, but 70% of the patients had relevant comorbidities. In an intention-to-treat analysis, the overall clinical response rate was 36%, the complete response rate was 2%, and the rate of partial remissions was 34%; stable disease occurred in 30%, and progressive disease was observed in 36%. Median duration of response was 10 months. Median time to progression was 4 months, and median overall survival time was 24 months.
The combination of pegylated liposomal doxorubicin and vinorelbine is an active and well tolerated regimen in elderly patients with metastatic breast cancer in first-line treatment.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A fast transversal filter (FTF) for the numerical factorization of polynomials having zeros of different modulus is presented. When all zeros of a polynomial are of different modulus, this algorithm can be used for the simultaneous determination of all zeros. This method is globally convergent in that it does not require initial conditions to start. Additionally, this can be modified to compute all zeros of any given polynomial by shifting the zeros. The numerical efficiency of this algorithm is inherited from the reduced computational cost associated with the transversal filters which require O(N) operations per sample and N is the order of the filter
    Acoustics, Speech, and Signal Processing, 1996. ICASSP-96. Conference Proceedings., 1996 IEEE International Conference on; 06/1996
  • [Show abstract] [Hide abstract]
    ABSTRACT: In modern oncology, paradigmatic developments can be witnessed with respect to conceptual strategies and to individualized diagnostics and treatment approaches, but foremost with respect to the amazing number of new anticancer substances available. These developments will certainly influence the care of patients suffering from incurable and advanced cancer, where pain therapy and symptom control, quality of life and other intentions of palliative care are urgent. For cancer pain therapy and palliative care, knowledge about these developments may be helpful not only with respect to interdisciplinary decision making, but also for thoroughly balancing risks, side effects and benefits of oncological interventions that have the potential to stabilize disease progression and thereby reduce symptom intensity.
    Der Schmerz 10/2010; 24(6):633-41. · 1.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Data on chemotherapy for elderly patients with metastatic breast carcinoma (MBC) are limited. We performed a 7-year retrospective analysis of MBC patients at our institution receiving first-line chemotherapy aged ≥75 years. Of 117 patients, 103 received monotherapy (67 capecitabine, 29 vinorelbine, 5 docetaxel, 2 liposomal doxorubicin) and 14 received polychemotherapy (12 anthracycline-based, 2 vinorelbine-gemcitabine). Chemotherapy demonstrated acceptable tolerability. Median progression-free survival (PFS) and overall survival (OS) from initiation of chemotherapy were 6.2 months and 13.8 months, respectively. At 2 years, 25% of patients were alive; however, 25% died within 3 months of beginning chemotherapy. Independent prognostic factors for longer PFS were good performance status, absence of visceral disease and capecitabine treatment. Good performance status and lack of visceral disease were also significant for OS. These results suggest that palliative chemotherapy should not be systematically excluded in this setting, but should be carefully discussed as it appears to be feasible with apparent benefit in selected patients.
    Critical reviews in oncology/hematology 10/2010; 80(1):171-9. DOI:10.1016/j.critrevonc.2010.10.002 · 4.05 Impact Factor